Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
|
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [31] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer
    Philipp Horvath
    Stefan Beckert
    Florian Struller
    Alfred Königsrainer
    Marc André Reymond
    Clinical & Experimental Metastasis, 2018, 35 : 635 - 640
  • [32] Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Martin Graversen
    Sönke Detlefsen
    Jon Kroll Bjerregaard
    Per Pfeiffer
    Michael Bau Mortensen
    Clinical & Experimental Metastasis, 2017, 34 : 309 - 314
  • [33] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program
    Luksta, Martynas
    Bausys, Augustinas
    Gendvilaite, Neda
    Bickaite, Klaudija
    Rackauskas, Rokas
    Paskonis, Marius
    Luksaite-Lukste, Raminta
    Ranceva, Anastasija
    Stulpinas, Rokas
    Brasiuniene, Birute
    Baltruskeviciene, Edita
    Lachej, Nadezda
    Bausiene, Juste
    Poskus, Tomas
    Bausys, Rimantas
    Tulyte, Skaiste
    Strupas, Kestutis
    CANCERS, 2024, 16 (17)
  • [34] Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
    Blanco, Ana
    Giger-Pabst, Urs
    Solass, Wiebke
    Zieren, Juergen
    Reymond, Marc A.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (07) : 2311 - 2316
  • [35] Environmental safety during the administration of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
    Graversen, Martin
    Pedersen, Peter B.
    Mortensen, Michael B.
    PLEURA AND PERITONEUM, 2016, 1 (04) : 203 - 208
  • [36] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects
    Solass, Wiebke
    Giger-Pabst, Urs
    Zieren, Juergen
    Reymond, Marc A.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (11) : 3504 - 3511
  • [37] Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei
    Robella, Manuela
    Vaira, Marco
    Borsano, Alice
    Mossetti, Claudio
    De Simone, Michele
    ANTICANCER RESEARCH, 2018, 38 (02) : 929 - 932
  • [38] Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
    Ana Blanco
    Urs Giger-Pabst
    Wiebke Solass
    Jürgen Zieren
    Marc A. Reymond
    Annals of Surgical Oncology, 2013, 20 : 2311 - 2316
  • [39] Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis
    Di Giorgio, Andrea
    Schena, Carlo Alberto
    El Halabieh, Miriam Attalla
    Abatini, Carlo
    Vita, Emanuele
    Strippoli, Antonia
    Inzani, Frediano
    Rodolfino, Elena
    Romano, Bruno
    Pacelli, Fabio
    Rotolo, Stefano
    SURGICAL ONCOLOGY-OXFORD, 2020, 34 : 270 - 275
  • [40] Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Sgarbura, Olivia
    Eveno, Clarisse
    Alyami, Mohammad
    Bakrin, Naoual
    Guiral, Delia Cortes
    Ceelen, Wim
    Delgadillo, Xavier
    Dellinger, Thanh
    Di Giorgio, Andrea
    Kefleyesus, Amaniel
    Khomiakov, Vladimir
    Mortensen, Michael Bau
    Murphy, Jamie
    Pocard, Marc
    Reymond, Marc
    Robella, Manuela
    Rovers, Koen P.
    So, Jimmy
    Somashekhar, S. P.
    Tempfer, Clemens
    Van der Speeten, Kurt
    Villeneuve, Laurent
    Yong, Wei Peng
    Hubner, Martin
    PLEURA AND PERITONEUM, 2022, 7 (01) : 1 - 7